{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
M017
(2023)
Source URL:
First approved in 2023
Source:
M017
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Tiger Pain by ZHENGZHOU GIANT BIOCHEMISTRY GROUP CO.,LTD
(2023)
Source URL:
First approved in 2023
Source:
Tiger Pain by ZHENGZHOU GIANT BIOCHEMISTRY GROUP CO.,LTD
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2023)
Source URL:
First approved in 2023
Source:
505G(a)(3)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
iShancare Pain Relief Patch by Shenzhen Ishan Technology Co., Ltd
(2023)
Source URL:
First approved in 2023
Source:
iShancare Pain Relief Patch by Shenzhen Ishan Technology Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT00412763: Phase 4 Interventional Completed Hepatitis
(2003)
Source URL:
First approved in 2023
Source:
M006
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Xinhuazhx Varicoce Veins Plaster by Puning Xinhua Trade Co., Ltd.
(2023)
Source URL:
First approved in 2023
Source:
Xinhuazhx Varicoce Veins Plaster by Puning Xinhua Trade Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE